To mitigate adverse immune responses, researchers can modify the surface properties of nanoparticles, such as by coating them with biocompatible materials. Another approach is to use targeted delivery systems that direct nanomaterials to specific tissues, thereby minimizing systemic exposure. Additionally, thorough preclinical testing can help identify potentially immunogenic materials before clinical application.
